Weekender 7/24/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. It’s been an important week at BioNJ…one of those where we just cannot contain our excitement! (Actually to be honest, they are all pretty much like that!!!) What has us particularly excited about this week though, is that FDA Commissioner Dr. Stephen Ostroff… Read the full article


Weekender 7/17/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. Another Great Week for New Jersey Approvals Basking Ridge-based BioNJ Member Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, announced that the FDA has approved its supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult… Read the full article


Weekender 7/10/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. LOTS OF GREAT NEWS THIS WEEK:  21st Century Cures Passes House by Wide Margin; Newx2 BioCruise Breaks Record Registration; Novartis Wins FDA Nod; Sanofi/Regeneron Drug Passes Hurdle; Celgene Announces Purchase of Merck Summit Campus; NJ Women Lead Scoring at World Cup An… Read the full article


Weekender 7/2/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. Celgene Expansion: Exciting News for the State of New Jersey  and Our Robust Ecosystem! BioNJ Member Celgene Corporation, an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases,… Read the full article


Weekender 6/26/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. BIG News for New Jersey Drug Approvals This Week BioNJ Member The Medicines Company announced the approval of KENGREAL™ (cangrelor) by the FDA as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been… Read the full article


Weekender 6/19/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. A special thank you to BIO International for holding this year’s annual conference in our region. BIO 2015, held this week at Pennsylvania Convention Center, June 15-18, was a huge success and represented our industry brilliantly! Thank you to everyone who… Read the full article


Weekender 6/5/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. New Jersey Companies Continue Progress in Drug Development Edge Therapeutics, a BioNJ Member located in Berkeley Heights, announced that the U.S. Food and Drug Administration has granted orphan drug designation to EG-1962, the Company’s lead product candidate, which is in clinical… Read the full article


Weekender 5/29/15

To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender. Congratulations to four New Jersey companies that received Food and Drug Administration (FDA) approvals. These wonderful accomplishments shine a positive light on the dynamic life sciences ecosystem in New Jersey. We can’t wait to share more of your positive news throughout… Read the full article


Weekender 5/22/15

To Our New Jersey Life Sciences Community: Welcome to another edition of The Weekender. Federal Research Bill Holds Promise for ‘Personalized Medicine’ in New Jersey The House Energy and Commerce Committee unanimously approved the 21st Century Cures Act, 51-0. The legislation has earned rave reviews across New Jersey’s research community, as well as its biotechnology and… Read the full article


Weekender 5/15/15

To Our New Jersey Life Sciences Community: Welcome to another edition of The Weekender. It’s Been a Banner Week for the New Jersey Life Sciences Community At the State level, Biosimilars legislation (A2477) was approved by the Assembly in a unanimous vote (72-0). This legislation allows pharmacists to substitute biosimilar products as long as the… Read the full article